

Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

NuVim, Inc.

332 Broughton Drive Myrtle Beach South Carolina 29579

201 788 5670

NuVim.com

info@NuVim.com

SIC Code: 20249905

Quarterly Report

For the period ending September 30, 2025 (the “Reporting Period”)

Outstanding Shares

The number of shares outstanding of our Common Stock was:

112,864,821 as of December 31, 2023

116,114,821 as of December 31, 2024

119,114,821 as of September 30, 2025

Shell Status

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: No:

Indicate by check mark whether the company’s shell status has changed since the previous reporting period:

Yes: No:

Change in Control

Indicate by check mark whether a Change in Control¹ of the company has occurred over this reporting period:

¹ “Change in Control” shall mean any events resulting in:

- (i) Any “person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the “beneficial owner” (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company’s then outstanding voting securities;
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company’s assets;
- (iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity

Yes: No:

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

The issuer's name is NuVim, Inc. It has never used another name.

Current State and Date of Incorporation or Registration: Delaware

Standing in this jurisdiction: (e.g. active, default, inactive): Active

Prior Incorporation Information for the issuer and any predecessors during the past five years:

None

Describe any trading suspension or halt orders issued by the SEC or FINRA concerning the issuer or its predecessors since inception:

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

The address(es) of the issuer's principal executive office:

332 Broughton Drive Myrtle Beach, South Carolina 29579

The address(es) of the issuer's principal place of business:

Check if principal executive office and principal place of business are the same address:

N/A

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No: Yes: If Yes, provide additional details below:

N/A

2) Security Information

Transfer Agent

Name: Equiniti Trust Company LLC

Phone: 800.937.5449

Email: help@astfinancial.com, newbusiness@astfinancial.com or brosenthal@astfinancial.com

Address: 6201 15th Avenue, Brooklyn, NY 11219

or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

Publicly Quoted or Traded Securities:

The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.

Trading symbol: NUVM
Exact title and class of securities outstanding: Common Stock
CUSIP: 67071X100
Par or stated value: \$0.00001 par value per share.
Total shares authorized: 120,000,000 as of date: September 30, 2025
Total shares outstanding: 119,114,821 as of date: September 30, 2025
Total number of shareholders of record: 216 as of date: September 30, 2025

Please provide the above-referenced information for all other publicly quoted or traded securities of the issuer.

None

Other classes of authorized or outstanding equity securities that do not have a trading symbol:

The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g., preferred shares that do not have a trading symbol). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.

Exact title and class of the security: None
Par or stated value: _____
Total shares authorized: _____ as of date: _____
Total shares outstanding: _____ as of date: _____
Total number of shareholders of record: _____ as of date: _____

Please provide the above-referenced information for all other classes of authorized or outstanding equity securities.

None

Security Description:

The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:

- 1. For common equity, describe any dividend, voting and preemption rights.**

Common Stockholders would receive dividends if and when declared from available surpluses by NuVim's Board of Directors. Each Common share is entitled to one vote on all company matters. There are no preemptive rights.

2. **For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.**

There are no preferred shares currently issued

3. **Describe any other material rights of common or preferred stockholders.**

NONE

4. **Describe any material modifications to the rights of the holders of the company's securities that have occurred over the reporting period covered by this report.**

NONE

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period.**

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No: Yes: X (If yes, you must complete the table below)

Shares Outstanding as of Second Most Recent Fiscal Year End: <u>Opening Balance</u>			*Right-click the rows below and select "Insert" to add rows as needed.						
Date <u>December 31, 2022</u>									
Common: <u>106,664,821</u> Preferred: <u>NONE</u>									
Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) OR Nature of Services Provided (if applicable)	Restricted or Unrestricted as of this filing?	Exemption or Registration Type?
4/17/2023	New	1,000,000	Common	\$5,000	No	Derek Spence	Cash	Restricted	Private Issue
7/17/2023	New	500,000	Common	\$1,000	No	Patrick Riggs	Cash	Restricted	Private Issue
7/17/2023	New	1,000,000	Common	\$3,000	No	Derek Spence	Cash	Restricted	Private Issue

7/17/2023	New	400,000	Common	\$1,000	No	Jason Lui	Cash	Restricted	Private Issue
7/25/2023	New	100,000	Common	\$2,500	No	Patrick Riggs	Cash	Restricted	Private Issue
10/17/2023	New	2,200,000	Common	\$8,800	No	Richard Kundrat	Services	Restricted	Private Issue
11/3/2023	New	1,000,000	Common	\$3,000	No	Derek Spence	Cash	Restricted	Private Issue
3/8/2024	New	1,750,000	Common	\$3,000	No	Derek Spence	Cash	Restricted	Private Issue
7/2/2024	New	750,000	Common	\$3,750	No	James Cushman	Cash	Restricted	Private Issue
7/2/2024	New	750,000	Common	\$3,750	No	Justin Pagel	Cash	Restricted	Private Issue
1/15/25	New	3,000,000	Common	\$15,000	No	Michael Ryan	Cash	Restricted	Private Issue
Shares Outstanding on the date of this Report: 9/30/2025 Common <u>119,114,821</u> Preferred: None									

Example: A company with a fiscal year end of December 31st, in addressing this item for its quarter ended September 30, 2022, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2020 through September 30, 2022 pursuant to the tabular format above.

Use the space below to provide any additional details, including footnotes to the table above:

N/A

B. Promissory and Convertible Notes

Indicate by check mark whether there are any outstanding promissory, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities:

No: Yes: X (If yes, you must complete the table below)

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder. *You must disclose the control person(s) for any entities listed.	Reason for Issuance (e.g. Loan, Services, etc.)
3/29/2011	\$33,236	\$25,000	\$8,083	4/1/24	None	Craig Laughlin	Loan

Use the space below to provide any additional details, including footnotes to the table above: None.

4) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations.

(Please ensure that these descriptions are updated on the Company's Profile on www.otcmarkest.com).

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

NuVim, Inc. (the Company) founded in 1999, specializes in producing, marketing, and distributing powder mix dietary supplements under the NuVim brand. The Company provides consumers with products that help bring an overall better quality of life and help address specific health concerns. Specifically, the current NuVim products help strengthen the immune system, enhance muscle, and bone health and aid in consistent digestion while delivering 100% of the daily requirement of vitamins C, E, B12, and zinc. There are 3 varieties of the powder mix products, Chocolate, Vanilla, and Strawberry, sold from the NuVim web site at www.nuvm.online. Each box contains 30 individually foil lined packets which is a one-month supply. The consumer adds the NuVim powder mix to yogurt, cereal, water juice and other beverages and foods. All product health benefit claims are based on the date of manufacture.

In past years NuVim has also marketed NuVim in ready-to-drink bottles sold from the refrigerated juice section of supermarkets, military commissaries, and Wal-Mart. Distribution was from Maine to Florida and as far west as Michigan. Due to lack of funding from the key investor group at the time the Company had to redesign their business model. A longer-term goal is to again market ready to drink products and develop a venture with a business to incorporate the NuVim health ingredients into their products.

A new improved formula of 5 varieties of the powder mix product line has been developed, taste tested and tested for extended shelf life. These products have been developed with the assistance of dietitians, Doctor John St. Cyr, and other resource groups including professional product development specialists. Doctor St. Cyr has been retained as a consultant going forward and will endorse the reformulated products when they are introduced to the market.

These new products incorporate a unique combination of compounds in the right amounts to provide a level of antioxidants designed to help neutralize free radicals, thus maintaining healthy functioning body cells and enhancing immune health and cardiovascular health, muscle and bone strength and mental acuity. There is also a prebiotic included to increase beneficial bacteria in the gut, indigenous to the digestive system. The new NuVim has compounds that promote healthy skin and a much shorter recovery time when feeling fatigued and run down. All compounds are considered by the FDA as Generally Recognized as Safe (GRAS).

The all-natural product line does not contain caffeine, fat, cholesterol, gluten, lactose, or a high caloric level. There are less than 20 calories per serving. The products deliver a good source of fiber, prebiotics for beneficial bacterial growth, vitamins C, E, B12, D3, and L-Citrulline.

The reformulated product is excellent for professional and amateur athletes, the weekend warrior and busy everyday consumers who want to live a healthier, more energetic quality of life.

In addition to the new product line growth initiative, the Company has evaluated several potential partnerships in the form of joint ventures, technology license agreements, or mergers. Ongoing discussions continue with one potentially interested private entities. The Company has approximately \$33000 in short-term debt. This is a significant improvement of the balance sheet from 2015 when the debt load was \$1.2 million. This task was accomplished without a significant dilution of the shareholders. Total shares outstanding is approximately 114 million. There are 120 million common shares authorized and 65 million preferred authorized. No preferred shares are outstanding. Annual and Quarterly filings with the Over-the-Counter Markets have been complete and on schedule for several years.

Company revenue has been limited due to the anticipation of the new product launch and potential agreement with private entities.

B. List any subsidiaries, parent company, or affiliated companies.

None

C. Describe the issuers' principal products or services.

The NuVim dietary supplement products are marketed to both men and women in all stages of life and to help professional athletes, weekend warriors, and those incurring immune dysfunction or lack of energy and mental alertness.

5) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer. Describe the location of office space, data centers, principal plants, and other property of the issuer and describe the condition of the properties. Specify if the assets, properties, or facilities are owned or leased and the terms of their leases. If the issuer does not have complete ownership or control of the property, describe the limitations on the ownership.

NuVim's headquarters is located in Myrtle Beach Lewes, Delaware. No manufacturing facilities are owned by NuVim. The products are co-packed under NuVim quality control supervision. No offices or distribution facilities are owned by NuVim. To control administrative costs, future sales of the new products will be generated through broker networks on a commission basis, through direct sales, through e-commerce and through prearranged contractual agreements. The Company has moved their corporate office to Myrtle Beach, South Carolina .

6) Officers, Directors, and Control Persons

Using the table below, please provide information, as of the period end date of this report, regarding any officers, or directors of the company, individuals or entities controlling more than 5% of any class of the issuers' securities, or any person that performs a similar function, regardless of the number of

shares they own. **If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.**

Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Names of All Officers, Directors and Control Persons	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Names of control person(s) if a corporate entity
Richard P. Kundrat	Officer, Director & 5% plus Owner	Lewes, DE	22,274,235	Common	19.2%	N/A
Peter DeCrescenzo	Director	The Villages, FL	533,333	Common	>1%	N/A
Michael Maizes	Director	Purchase, NY	1,604,000	Common	1.4%	N/A
Estate of Dick Clark	5% plus owner	Malibu, CA	6,658,637	Common	5.7%	Kari W. Clark, Executrix
Derek R. Spense	5% plus owner	Mashpee, MA	9,500,000	Common	8.0%	Derek R. Spense
Estate of Stanley Moger	5% plus Owner	Purchase, NY	6,402,955	Common	5.5%	Michael Maizes, Executor

7) Legal/Disciplinary History

- A. Identify whether any of the persons or entities listed above have, in the past 10 years:
1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations). NONE
 2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities. NONE
 3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated. NONE
 4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; NONE or
 5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities. NONE
 6. Been the subject of a U.S. Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S. mail. NONE
- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities. NONE

8) Third Party Service Providers

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.

Securities Counsel (must include Counsel preparing Attorney Letters).

Name: Mark A. Siegel, Esq.
Address 1: 7067 Trentino Way
Address 2: Boynton Beach, FL, 33472
Phone: 561.212.8035
Email: masiegel@gate.net

Accountant or Auditor

Name: Richard P. Kundrat
Firm: _____
Address 1: 18327 Port Circle

Address 2: Myrtle Beach, South Carolina Lewes DE 19958
Phone: 201 788 5670302.827.4052
Email: rpkundrat@yahoo.com

Investor Relations

Name: None
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

All other means of Investor Communication:

X (Twitter): _____
Discord: _____
LinkedIn: _____
Facebook: _____
[Other]: _____

Other Service Providers

Provide the name of any other service provider(s) that that assisted, advised, prepared, or provided information with respect to this disclosure statement. This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

Name: None
Firm: _____
Nature of Services: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

9) Financial Statements

A. This Disclosure Statement was prepared by (name of individual):

Name: Mark Alan Siegel, Esq
Title: None
Relationship to Issuer: Securities Counsel

B. The following financial statements were prepared in accordance with:

IFRS
 U.S. GAAP

c. The following financial statements were prepared by (name of individual)²:

Name: Richard P. Kundrat

Title: CFO

Relationship to Issuer: Officer

Describe the qualifications of the person or persons who prepared the financial statements: Mr. Kundrat founded NuVim, Inc. in 1999 and has been the only CEO of the Company. He was employed by Unilever/Lipton for 27 years starting as a salesperson and moving through the organization with assignments in promotion, advertising, new products' national introductions, and marketing. He ended his career at Lipton as the Vice President and General Manager of the North American Pepsi/Lipton Tea 75-year partnership. The Partnership includes manufacturing, marketing and distribution of all Lipton tea in bottles and cans and fountain. In the third year of the Partnership retail sales exceeded one billion dollars. The Partnership now operates in over sixty countries. The Partnership structure was developed by Mr. Kundrat in conjunction with a Pepsi executive and signed by the Lipton and Pepsi CEOs.

Provide the following financial statements for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- a. Audit letter, if audited;
- b. Balance Sheet;
- c. Statement of Income;
- d. Statement of Cash Flows;
- e. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- f. Financial Notes
- g. Management Discussion and Analysis

Financial Statement Requirements:

- Financial statements must be published together with this disclosure statement as one document.
- Financial statements must be "machine readable". Do not publish images/scans of financial statements.
- Financial statements must be presented with comparative financials against the prior FYE or period, as applicable.
- Financial statements must be prepared in accordance with U.S. GAAP or International Financial Reporting Standards (IFRS) but are not required to be audited.

² The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

NuVim, Inc,
Balance Sheets (unaudited)

	September 30, 2025	December 31, 2024
ASSETS		
Current assets:		
Cash and cash equivalents	\$ -	\$ 719
Prepaid	5,625	3,060
Total current assets	5,625	3,779
 Total assets	 \$ 5,625	 \$ 3,779
LIABILITIES & STOCKHOLDERS' DEFICIT		
Current liabilities:		
Accounts payable	\$ 1,350	\$ 8,871
Notes payable - current portion	33,236	32,786
Total current liabilities	34,586	41,657
 Commitments & contingencies	 -	 -
 Total liabilities	 34,586	 41,657
 Stockholders' Deficit:		
Common Stock, 120,000,000 shares authorized, \$.00001 par value, 119,114,821 shares issued and outstanding at September 30, 2025 and 116,114,821 outstanding at December 31, 2024	1,192	1,162
Additional paid-in capital	24,933,480	24,910,110
Accumulated deficit	(24,963,633)	(24,949,150)
Total stockholders' deficit	(28,961)	(37,878)
 Total liabilities and stockholders' deficit	 \$ 5,625	 \$ 3,779

See the accompanying notes to the unaudited financial statements

NuVim, Inc,
Balance Sheets (unaudited)

	September 30, 2025	December 31, 2024
ASSETS		
Current assets:		
Cash and cash equivalents	\$ -	\$ 719
Prepaid	5,625	3,060
Total current assets	5,625	3,779
 Total assets	 \$ 5,625	 \$ 3,779
LIABILITIES & STOCKHOLDERS' DEFICIT		
Current liabilities:		
Accounts payable	\$ 1,350	\$ 8,871
Notes payable - current portion	33,236	32,786
Total current liabilities	34,586	41,657
 Commitments & contingencies	 -	 -
 Total liabilities	 34,586	 41,657
Stockholders' Deficit:		
Common Stock, 120,000,000 shares authorized, \$.00001 par value, 119,114,821 shares issued and outstanding at September 30, 2025 and 116,114,821 outstanding at December 31, 2024	1,192	1,162
Additional paid-in capital	24,933,480	24,910,110
Accumulated deficit	(24,963,633)	(24,949,150)
Total stockholders' deficit	(28,961)	(37,878)
 Total liabilities and stockholders' deficit	 \$ 5,625	 \$ 3,779

See the accompanying notes to the unaudited financial statements

NuVim, Inc,
Statement of Operations (unaudited)

	Three months ended September 30,		Periods ended September 30,	
	2025	2024	2025	2024
Gross sales	\$ 200	\$ -	\$ 400	\$ 447
Gross profit	200	-	400	447
Selling, general and administrative expenses	3,796	6,686	14,433	16,464
Loss from operations	(3,596)	(6,686)	(14,034)	(16,017)
Other income (expense)				
Interest expense	(153)	(152)	(450)	(450)
Total other income (expense)	(153)	(152)	(450)	(450)
Net loss before income tax	(3,749)	(6,838)	(14,484)	(16,467)
Income taxes (benefit)	-	-	-	-
Net loss	<u>\$ (3,749)</u>	<u>\$ (6,838)</u>	<u>\$ (14,484)</u>	<u>\$ (16,467)</u>
Basic and diluted loss per share	<u>0.00</u>	<u>0.00</u>	<u>0.00</u>	<u>0.00</u>
Weighted average number of common shares outstanding - basic and diluted	<u>119,114,821</u>	<u>114,614,821</u>	<u>118,565,370</u>	<u>114,678,690</u>

See the accompanying notes to the unaudited financial statements

NuVim, Inc,
Condensed Statement of Stockholders' Deficit (unaudited)
Three Months Ended September 30, 2025 and 2024

	Common Stock		Additional Paid in Capital	Common Stock Subscription	Accumulated Deficit	Total
	Shares	Amount				
Balance, June 30, 2025	119,114,821	\$ 1,192	\$ 24,925,081	\$ -	\$ (24,959,885)	\$ (33,613)
Contribution of capital	-	-	8,400	-	-	8,400
Net Loss	-	-	-	-	(3,749)	(3,749)
Balance, September 30, 2025	119,114,821	\$ 1,192	\$ 24,933,481	\$ -	\$ (24,963,633)	\$ (28,961)

	Common Stock		Additional Paid in Capital	Common Stock Subscription	Accumulated Deficit	Total
	Shares	Amount				
Balance, June 30, 2024	114,614,821	\$ 1,147	\$ 24,902,625	\$ 7,500	\$ (24,938,473)	\$ (27,201)
Subscription received from sale of common stock	1,500,000	15	7,485	(7,500)	-	-
Net Loss	-	-	-	-	(6,837)	(6,837)
Balance, September 30, 2024	116,114,821	\$ 1,162	\$ 24,910,110	\$ -	\$ (24,945,310)	\$ (34,038)

See the accompanying notes to the condensed unaudited financial statements

NuVim, Inc,
Statement of Stockholders' Deficit (unaudited)
Periods ended September 30, 2025 and 2024

	Common Stock		Additional Paid in Capital	Accumulated Deficit	Total
	Shares	Amount			
Balance, December 31, 2024	116,114,821	\$ 1,162	\$ 24,910,110	\$ (24,949,149)	\$ (37,878)
Proceeds from sale of common stock	3,000,000	30	14,970	-	15,000
Contribution of capital	-	-	8,400	-	8,400
Net Loss	-	-	-	(14,484)	(14,483)
Balance, September 30, 2025	119,114,821	\$ 1,192	\$ 24,933,481	\$ (24,963,633)	\$ (28,961)

	Common Stock		Additional Paid in Capital	Accumulated Deficit	Total
	Shares	Amount			
Balance, December 31, 2023	112,864,821	\$ 1,129	\$ 24,899,643	\$ (24,928,843)	\$ (28,071)
Proceeds from sale of common stock	3,250,000	33	10,467	-	10,500
Net Loss	-	-	-	(16,468)	(16,468)
Balance, September 30, 2024	116,114,821	\$ 1,162	\$ 24,910,110	\$ (24,945,311)	\$ (34,039)

See the accompanying notes to the unaudited financial statements

NuVim, Inc,
Statements of Cash Flows (unaudited)

	For the periods ended September 30,	
	2025	2024
Cash Flows From Operating Activities:		
Net Loss	\$ (14,483)	\$ (16,467)
Changes in Operating Assets and Liabilities		
Prepaid expenses	(2,565)	(1,620)
Accounts payable and accrued expenses	(7,071)	6,741
Net cash used in operating activities	(24,119)	(11,346)
Cash Flows From Investing Activities:	-	-
Cash Flows From Finance Activities:		
Proceeds from sale of common stock	15,000	10,500
Contribution of capital	8,400	-
Net Cash Provided by Finance Activities	23,400	10,500
Net increase in cash and cash equivalents	(719)	(846)
Cash and cash equivalents, beginning of the year	719	1,234
Cash and cash equivalents, end of the year	\$ 0	\$ 388
Supplemental disclosures of cash flow information:		
Cash paid during the period for interest	-	-
Cash paid during the period for income taxes	-	-

See the accompanying notes to the unaudited financial statements

NuVim, Inc,
Statements of Cash Flows (unaudited)

	For the periods ended September 30,	
	2025	2024
Cash Flows From Operating Activities:		
Net Loss	\$ (14,483)	\$ (16,467)
Changes in Operating Assets and Liabilities		
Prepaid expenses	(2,565)	(1,620)
Accounts payable and accrued expenses	(7,071)	6,741
Net cash used in operating activities	(24,119)	(11,346)
Cash Flows From Investing Activities:	-	-
Cash Flows From Finance Activities:		
Proceeds from sale of common stock	15,000	10,500
Contribution of capital	8,400	-
Net Cash Provided by Finance Activities	23,400	10,500
Net increase in cash and cash equivalents	(719)	(846)
Cash and cash equivalents, beginning of the year	719	1,234
Cash and cash equivalents, end of the year	\$ 0	\$ 388
Supplemental disclosures of cash flow information:		
Cash paid during the period for interest	-	-
Cash paid during the period for income taxes	-	-

See the accompanying notes to the unaudited financial statements

NuVim, Inc.

Financial Notes (unaudited)

BUSINESS

Currently NuVim (the “Company”) is working to finance the company through friends and current investors to maintain current payables and to realign the business.

NuVim, Inc.

Management's Discussion and Analysis of Financial Condition and Results of Operations during the Three quarters ended September 30, 2025

A) Results of Operations

Results of operations for the three quarters ended September 30, 2025, compared to the three quarters ended September 30, 2024

Sales For the three quarters ended September 30, 2025, there were gross sales of 400, a decrease of \$47, from gross sales of \$447 for the three quarters ended September 30, 2024. This decrease for the three quarters is the result of virtual exhaustion of the remaining inventory of current products. The plan is to replace the currently formulated products with a new improved powder mix product line. The second initiative the Company has been pursuing is a potential collaboration with another company that would improve both companies' revenue and profits. The Company is diligently working to achieve a potential collaboration with another company. The Company has for the past several months been in discussions with other candidates that has both significant revenues and profits and fit more closely with the NuVim product line of increasing consumer health benefits.

Cost of Sales NuVim was required to periodically assess the value of its inventory for impairment. Several years ago, the value of the inventory was reduced to zero. Therefore, NuVim's books reflect no cost for the inventory now being sold, The Company has eliminated most of the inventory.

Gross Profit There was a gross profit of \$400 for the Three quarters ended September 30, 2025, a decrease of 11% from \$447 for the three quarters ended September 30, 2024, the same as the reduction in Net Sales. As explained above, Gross profit as a percentage of gross sales was 100% during this Three quarters, the same as in 2024.

Selling, General and Administrative Expenses Selling, general and administrative expenses were \$14,034 for the three quarters ended September 30, 2025, down 13% from the \$16,017 for the three quarters ended September 30, 2024. This stability is due to management's continuing efforts to control expenses.

Loss from Operations Loss from operations was \$14,034 for the three quarters ended September 30, 2025, compared to \$16,017 for the three quarters ended September 30, 2024. The decrease of \$1,983 is a result of the management's expense discipline offset by reduced sales.

Interest Expense Interest expense was \$450 for the three quarters ended September 30, 2025, identical to the interest expense of \$450 for the three quarters ended September 30, 2024. This reflects the stability of the Company's debt.

Net Loss Net loss was \$14,484 for the three quarters ended September 30, 2025, compared to \$16,467 for the three quarters ended September 30, 2024. The decrease in the loss of \$1,983 is primarily due to the impact of the factors described above.

Results of operations for the Quarter ended September 30, 2025, compared to the Quarter ended September 30, 2024

Sales For the Quarter ended September 30, 2025, there were gross sales of \$200, more than the gross sales for the Quarter ended September 30, 2024. This is the result of virtual exhaustion of the remaining inventory of current products. The plan is to replace the currently formulated products with a new improved powder mix product line. The second initiative the Company has been pursuing is a potential collaboration with another company that would improve both companies' revenue and profits. The Company is diligently working to achieve a potential collaboration with another company. The Company has for the past several months been in discussions with other candidates that has both significant revenues and profits and fit more closely with the NuVim product line of increasing consumer health benefits.

Cost of Sales NuVim was required to periodically assess the value of its inventory for impairment. Several years ago, the value of the inventory was reduced to zero. Therefore, NuVim's books reflect no cost for the inventory now being sold, The Company has eliminated most of the inventory.

Gross Profit The gross profit for the Quarter ended September 30, 2025 was \$200, the same as for the Quarter ended September 30, 2024. As explained above, Gross profit as a percentage of gross sales was 100% during this Quarter, the same as in 2024.

Selling, General and Administrative Expenses Selling, general and administrative expenses were \$3,796 for the Quarter ended September 30, 2025, over 45% down from the \$6,686 for the Quarter ended September 30, 2024. The reduction is due to management's continuing efforts to control expenses.

Loss from Operations Loss from operations was \$5,250 for the Quarter ended September 30, 2025, compared to \$4,481 for the Quarter ended September 30, 2024. The decrease of \$769 is a result of the management's expense discipline offset by reduced sales.

Interest Expense Interest expense was \$153 for the Quarter ended September 30, 2025, almost identical to the interest expense of \$152 for the Quarter ended September 30, 2024. This reflects the stability of the Company's debt.

Net Loss Net loss was \$3,467 for the Quarter ended September 30, 2025, compared to \$6,838 for the quarter ended September 30, 2024. The decrease in the loss of \$3,089 is primarily due to the impact of the factors described above.

B. Liquidity and Capital Resources

Our operations to date have generated significant operating losses that have been funded through the issuance of common stock and external borrowings. We will require additional sources of outside capital to continue our current operations and to fund a collaboration with another company.

If we are not able to identify additional sources of financing, we may not be able to continue operations beyond December 2025.

NuVim's Shareholders' Deficit was \$24,963,633 on September 30, 2025, as compared with \$24,949,150 at the end of 2024, reflecting new capital raised offset by the \$14,848 net loss during the first three quarters. The Working Capital deficit at the end of this Quarter was \$28,961, compared to the Working Capital deficit of \$37,878 at the end of 2024.

Net cash used in operating activities for the three quarters ended September 30, 2025, was \$24,119 compared to cash used in operating activities of \$11,346 during the first three quarters of 2024.

\$23,400 was provided by financing activities during the first three quarters of 2025; compared to \$10,500 provided for the three quarters ended September 30, 2024.

As a result, there was no cash on hand as of September 30, 2025, as compared with \$719 at the end of December 2024.

D. Off-Balance Sheet Arrangements

NuVim does not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Richard P. Kundrat certify that:

1. I have reviewed this Disclosure Statement for NuVim, Inc.
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

October 26, 2025 [Date]

/s/ Richard P. Kundrat [CEO's Signature]

(Digital Signatures should appear as “/s/ [OFFICER NAME]”)

Principal Financial Officer:

I, Richard P. Kundrat certify that:

1. I have reviewed this Disclosure Statement for NuVim, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

October 26, 2025 [Date]

/s/ Richard P. Kundrat [CFO's Signature]

(Digital Signatures should appear as “/s/ [OFFICER NAME]”)